Labcorp and Circuit Clinical collaborate to bring clinical trials directly to patients and increase access to underrepresented populations

19 February 2021

Burlington, NC and Buffalo, NY – February 19, 2021 – Labcorp, (NYSE: LH), a leading global life sciences company, and Circuit Clinical®, a network of physicians and clinical research professionals devoted to and passionate about bringing clinical research to everyone, today announced a collaboration to bring clinical trials directly to patients in the places, and with the people, their communities trust most to deliver healthcare services. 

The multifaceted collaboration brings clinical trials to a broad and diverse patient population that otherwise may not have the chance to participate. While many doctors are interested in clinical trials, most do not have the facilities, staff, or time to conduct them, complicating efforts to ensure that trials represent a diverse patient population. The companies will work with a broad mix of Labcorp Diagnostics customers such as healthcare providers, physician groups, health systems, and Federally Qualified Health Centers (FQHCs), and will leverage Circuit Clinical’s ability to quickly create fully equipped, high-performing clinical trial sites from the ground up. Through its network of patient service centers and direct connections to millions of patients, Labcorp will also provide crucial information about upcoming clinical trials directly to qualifying individuals.

“We are delighted to be working closely with Circuit Clinical to increase patient access to clinical trials and leverage our complementary capabilities,” said Dr. Paul Kirchgraber, CEO, Labcorp Drug Development. “Diversity in trials is critical to the development of any new drug and is particularly important as we advance COVID-19 treatments. Our relationship with Circuit gives us the ability to engage with potential participants of all backgrounds, both now and in future clinical trials.” 

“This partnership will allow Labcorp to use the combined power of both our diagnostics and drug development segments to bring innovative medicines directly to the physicians and patients we serve,” said Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics. “We are excited to work with Circuit Clinical to bring high-quality clinical trials that focus on effective patient outcomes to our diagnostic customers.” 

The relationship will also further accelerate patient engagement and recruitment through the development of a Decentralized Clinical Trial (DCT) Investigator Network. This network aims to cultivate a broad nexus of physicians who can support decentralized clinical trials, accelerate patient recruitment, increase clinical trial access to more diverse patients, and reduce the burden of participation by supporting remote patient engagement. 

“Circuit Clinical is thrilled to be working with Labcorp to advance our shared commitment to decentralized clinical trials,” said Dr. Irfan Khan, founder and CEO of Circuit Clinical. “Our team of physician-innovators is driven to accelerate Labcorp’s mission to provide a superior patient experience, reduce their burden, and improve access to clinical trials for all.”

About Circuit Clinical

One of the largest Integrated Research Organizations in the USA, Circuit Clinical® is dedicated to transforming the way physicians and patients find, choose, and participate in clinical research. Circuit Clinical® delivers turnkey clinical research services and an award-winning patient engagement platform,

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020. Learn about Labcorp at, or follow us on LinkedIn and Twitter @Labcorp.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing and the potential benefits of a COVID-19 test home collection kit and our responses to and the expected future impacts of the COVID-19 pandemic and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
[email protected]

Investors: Chas Cook — 336-436-5076
[email protected]

Circuit Clinical Contact:

Jenna Crisp — 503-869-3339 

Source: Labcorp